Welcome to our dedicated page for Quidel news (Ticker: QDEL), a resource for investors and traders seeking the latest updates and insights on Quidel stock.
QuidelOrtho Corporation (Nasdaq: QDEL) is a global in vitro diagnostics company that regularly issues news on its products, technologies and financial performance. As a manufacturer of diagnostic solutions spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho generates updates that are relevant to clinicians, laboratory professionals and investors who follow developments in medical diagnostics.
News about QuidelOrtho often covers product clearances and launches, such as FDA 510(k) clearance for the VITROS hs Troponin I Assay to aid in the diagnosis of myocardial infarction, or the availability of the QUICKVUE Influenza + SARS Test, a CLIA‑waived rapid immunoassay that differentiates influenza A, influenza B and SARS‑CoV‑2 from a single sample. These announcements provide insight into how the company is expanding its cardiac, respiratory and point‑of‑care testing portfolios.
The company also issues financial and corporate updates, including quarterly earnings releases, guidance discussions and details of financing arrangements disclosed through press releases and related SEC filings. Investors can track how QuidelOrtho describes its revenue mix, cost‑savings initiatives and capital structure, including credit agreements and refinancing activities.
Another recurring theme in QuidelOrtho’s news flow is educational and thought‑leadership content. Through its Science Bytes podcast, the company highlights topics such as diagnostic trends, early detection of diabetes, the role of informatics in clinical decision‑making and the importance of respiratory testing in urgent care. Episodes feature internal experts and external clinicians and are used to explain how diagnostics intersect with patient care and healthcare economics.
In addition, QuidelOrtho reports on its participation in industry conferences, including events focused on transfusion medicine where it showcases immunohematology products like the MTS DAT Card and ORTHO VISION Platform. For users of this news page, following QDEL news offers a way to monitor product pipeline milestones, regulatory developments, financial disclosures and educational initiatives from a single diagnostics-focused source.
As Lyme disease season approaches, Quidel Corporation emphasizes the importance of awareness and testing. Up to 400,000 Americans are infected annually, with symptoms often mimicking COVID-19. Dr. Judi Tilghman advises outdoor enthusiasts to take precautionary measures against ticks and seek immediate testing if symptoms arise.
Quidel’s Sofia® 2 Lyme test offers rapid results, aiding timely diagnosis and treatment. The company's mission focuses on providing accessible, accurate health diagnostics, enhancing patient care across diverse health conditions.
Quidel Corporation (NASDAQ: QDEL) has received Emergency Use Authorization (EUA) from the FDA for its Sofia® SARS Antigen FIA. This test detects SARS-CoV-2 antigens from nasal swabs, allowing usage without a prescription for asymptomatic individuals under specific testing conditions. The test shows a strong correlation with PCR results (96.7% agreement for positives, 100% for negatives) within five days of symptom onset. While the company aims for broad application to enhance early detection, ongoing studies seek to confirm clinical performance among asymptomatic patients.
Quidel Corporation (NASDAQ: QDEL) has been named the Official Diagnostics Partner of the San Diego Padres, a Major League Baseball franchise. Quidel will supply its Sofia® 2 instruments and Sofia® SARS Antigen tests to support the Padres' medical staff and event personnel, enhancing safety measures at Petco Park. This partnership aims to ensure a safe experience for attendees during games, with rapid test results delivered in just 15 minutes. Quidel has been at the forefront of COVID-19 testing innovation, underscoring its commitment to public health in the San Diego community.
Quidel (NASDAQ: QDEL) announced a partnership with the CDC and NIH for the “Say Yes! COVID Test” initiative in Pitt County, NC, and Chattanooga, TN. The program aims to distribute two million free QuickVue® At-Home OTC COVID-19 Tests to approximately 160,000 residents. This innovative study assesses whether regular access to at-home antigen tests can effectively reduce virus transmission in vulnerable communities. The QuickVue test is user-friendly, delivering results in 10 minutes with high accuracy rates. This initiative seeks to provide foundational data to inform future pandemic responses.
Quidel Corporation (NASDAQ: QDEL) has received Emergency Use Authorization (EUA) from the FDA for its QuickVue® At-Home OTC COVID-19 Test. This test enables qualitative detection of the SARS-CoV-2 nucleocapsid protein antigen, usable by individuals aged 14 and older, with results showing 83.5% agreement with PCR tests. Quidel is also expanding its manufacturing capabilities with a new facility in Carlsbad, CA, projected to produce over 50 million tests monthly. The QuickVue® brand has sold over 150 million tests since its inception.
Quidel Corporation (NASDAQ: QDEL) has expressed support for the Biden Administration's initiative to enhance COVID-19 testing across various communities. The company emphasizes the importance of frequent testing in safely reopening schools and institutions. Quidel recently received Emergency Use Authorization for its QuickVue® At-Home COVID-19 Test, aiming to expand access to testing without prescriptions. Additionally, the company is constructing a new 128,000 square foot manufacturing facility in Carlsbad, CA, expected to produce 600 million rapid antigen tests annually.
Quidel Corporation (NASDAQ: QDEL) has received Emergency Use Authorization (EUA) from the FDA for its QuickVue® At-Home COVID-19 Test. This test allows prescription home use for individuals aged 14 and older suspected of COVID-19 within six days of symptom onset.
The test provides results in 10 minutes, boasting an 84.8% agreement with PCR positive results and 99.1% for negatives. Quidel is expanding its manufacturing to produce over 50 million tests monthly at its new facility in California, enhancing access to rapid COVID-19 testing for consumers and healthcare providers.
Quidel Corporation (NASDAQ: QDEL) announced its participation in two upcoming virtual conferences. The first is the Raymond James 42nd Annual Institutional Investors Conference on March 2, 2021, at 11:40 a.m. ET, followed by the Barclays Global Healthcare Conference on March 10, 2021, at 1:15 p.m. ET. Presenters will include CEO Douglas Bryant and CFO Randy Steward, discussing business and financial developments. Live webcasts will be accessible via the company's Investor Relations website, with replays available for 14 days.
Quidel Corporation (NASDAQ: QDEL) reported robust financial results for Q4 and the full year 2020, showcasing a 432% surge in revenue to $809.2 million compared to Q4 2019. COVID-19 product sales reached $678.7 million. The company reported a GAAP EPS of $10.78 and a non-GAAP EPS of $11.07, significantly up from $0.71 and $1.00 respectively in the prior year. For the full year, revenue climbed 211% to $1.66 billion, driven mainly by its COVID-19 diagnostic offerings. New product launches and a strong balance sheet position Quidel for growth into 2021.
Quidel Corporation (NASDAQ: QDEL) has announced the opening of a new manufacturing facility in Carlsbad, CA, dedicated to producing its QuickVue® line of products. This 128,000 square-foot plant will enhance production capacity from 50 million tests annually to 600 million tests per year, specifically for QuickVue® SARS rapid antigen tests used for COVID-19 detection. Approximately 400 new jobs will be created as the company aims to scale its operations effectively.
The QuickVue® SARS Antigen Test has received Emergency Use Authorization from the FDA, demonstrating high accuracy in detecting COVID-19.